Key Takeaways
Genmab A/S (GMAB) reported a 25 percent increase in first-quarter revenue to $896 million and announced a favorable FDA decision for its cancer treatment, EPKINLY.
"We made tangible progress in the first quarter as we continue to integrate Merus™ and advance our late-stage portfolio - EPKINLY, Rina-S and petosemtamab," Jan van de Winkel, Chief Executive Officer at Genmab, said. "Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients."
The Danish biotechnology company's growth was supported by developments in its late-stage drug pipeline. The U.S. Food and Drug Administration approved a supplemental Biologics License Application (sBLA) for EPKINLY (epcoritamab), removing the need for a 24-hour hospital stay for certain patients with diffuse large B-cell lymphoma (DLBCL). This change makes the treatment more accessible for patients with third-line plus relapsed or refractory DLBCL.
Genmab reaffirmed its 2026 financial guidance originally published on February 17, 2026. The company's pipeline includes key assets obtained through its collaboration with AbbVie on EPKINLY and the integration of ProfoundBio, which brought Rina-S (rinatabart sesutecan) into its portfolio.
The positive FDA ruling for EPKINLY may lead to wider adoption and increased sales for the treatment. Investors will be watching for further details on the launch strategy and updates on the late-stage portfolio during the company's conference call scheduled for today at 6:00 pm CEST.
This article is for informational purposes only and does not constitute investment advice.
